JP2009538415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538415A5 JP2009538415A5 JP2009506735A JP2009506735A JP2009538415A5 JP 2009538415 A5 JP2009538415 A5 JP 2009538415A5 JP 2009506735 A JP2009506735 A JP 2009506735A JP 2009506735 A JP2009506735 A JP 2009506735A JP 2009538415 A5 JP2009538415 A5 JP 2009538415A5
- Authority
- JP
- Japan
- Prior art keywords
- steroid receptor
- receptor
- cancer
- immunoassay
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 39
- 108010085012 Steroid Receptors Proteins 0.000 claims description 34
- 102000005969 steroid hormone receptors Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 31
- 238000003018 immunoassay Methods 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 229940126588 endocrine therapeutic agent Drugs 0.000 claims description 5
- 102100032187 Androgen receptor Human genes 0.000 claims description 4
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 4
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims description 4
- 102100038595 Estrogen receptor Human genes 0.000 claims description 4
- 102100025803 Progesterone receptor Human genes 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 108010080146 androgen receptors Proteins 0.000 claims description 4
- 239000003886 aromatase inhibitor Substances 0.000 claims description 4
- 108090000468 progesterone receptors Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000009261 endocrine therapy Methods 0.000 claims description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims description 3
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
- 108010041356 Estrogen Receptor beta Proteins 0.000 claims description 2
- 102100029951 Estrogen receptor beta Human genes 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 229960000255 exemestane Drugs 0.000 claims description 2
- 229950011548 fadrozole Drugs 0.000 claims description 2
- 238000002875 fluorescence polarization Methods 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
- 210000004897 n-terminal region Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74501206P | 2006-04-18 | 2006-04-18 | |
| US60/745,012 | 2006-04-18 | ||
| PCT/US2007/066849 WO2007121459A2 (en) | 2006-04-18 | 2007-04-18 | Detection of steroid receptors on circulating carcinoma cells and treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538415A JP2009538415A (ja) | 2009-11-05 |
| JP2009538415A5 true JP2009538415A5 (enExample) | 2011-04-28 |
| JP5078100B2 JP5078100B2 (ja) | 2012-11-21 |
Family
ID=38610453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506735A Expired - Fee Related JP5078100B2 (ja) | 2006-04-18 | 2007-04-18 | 循環癌細胞におけるステロイド受容体の検出および処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090291920A1 (enExample) |
| EP (1) | EP2008107A4 (enExample) |
| JP (1) | JP5078100B2 (enExample) |
| CA (1) | CA2647743A1 (enExample) |
| MX (1) | MX2008013331A (enExample) |
| WO (1) | WO2007121459A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4798801B2 (ja) * | 2004-10-06 | 2011-10-19 | ウェルスタット バイオロジクス コーポレイション | 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置 |
| JP2010525326A (ja) * | 2007-04-19 | 2010-07-22 | ウェルスタット バイオロジックス コーポレイション | 分離されていない循環癌細胞由来のＨｅｒ−２／ｎｅｕタンパク質の上昇したレベルの検出および治療 |
| WO2009138130A1 (en) * | 2008-05-16 | 2009-11-19 | Atlas Antibodies Ab | Breast cancer prognostics |
| CA2804269A1 (en) * | 2010-07-07 | 2012-01-12 | The Regents Of The University Of Michigan | Diagnosis and treatment of breast cancer |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| EP2628008B1 (en) * | 2010-10-14 | 2017-05-31 | Janssen Diagnostics, LLC | Methods and kits for the detection of circulating tumor cells in pancreatic patients using polyspecific capture and cocktail detection reagents |
| US20120252038A1 (en) * | 2011-04-01 | 2012-10-04 | Chianese David A | Steroid receptor assays |
| EP2888594B1 (en) | 2012-08-23 | 2018-08-15 | The Regents of the University of Colorado, a body corporate | Method for determining breast cancer treatment |
| US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
| IT201800004137A1 (it) * | 2018-03-30 | 2019-09-30 | Domenico Marina Di | Metodo di screening in vitro per diagnosi precoce dei tumori del cavo orale e relativo kit, basato in particolare su saggio elisa |
| SG11202106924VA (en) * | 2019-01-03 | 2021-07-29 | Meso Scale Technologies Llc | Compositions and methods for carrying out assay measurements |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020172987A1 (en) * | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| EP1360496A4 (en) * | 2001-02-16 | 2005-03-09 | Immunivest Corp | METHOD AND REAGENTS FOR THE QUICK AND EFFICIENT INSULATION OF CIRCULATING CANCER CELLS |
| EP1597353B1 (en) * | 2003-02-27 | 2010-11-24 | Veridex, LLC | CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS |
| US7335735B2 (en) * | 2003-05-07 | 2008-02-26 | Cedars-Sinai Medical Center | Intracellular estradiol binding protein |
| JP4798801B2 (ja) * | 2004-10-06 | 2011-10-19 | ウェルスタット バイオロジクス コーポレイション | 循環する癌細胞におけるＨｅｒ−２／ｎｅｕタンパク質のレベルの上昇の検出および処置 |
| GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| US20100105145A1 (en) * | 2005-07-01 | 2010-04-29 | Dako Denmark A/S | Method of simultaneously visualizing multiple biological targets |
| EP1816477A1 (en) * | 2006-02-06 | 2007-08-08 | F. Hoffmann-la Roche AG | The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing |
-
2007
- 2007-04-18 CA CA002647743A patent/CA2647743A1/en not_active Abandoned
- 2007-04-18 MX MX2008013331A patent/MX2008013331A/es active IP Right Grant
- 2007-04-18 JP JP2009506735A patent/JP5078100B2/ja not_active Expired - Fee Related
- 2007-04-18 US US12/296,458 patent/US20090291920A1/en not_active Abandoned
- 2007-04-18 EP EP07760823A patent/EP2008107A4/en not_active Withdrawn
- 2007-04-18 WO PCT/US2007/066849 patent/WO2007121459A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538415A5 (enExample) | ||
| Salminen et al. | Associations between serum testosterone fall and cognitive function in prostate cancer patients | |
| Ersöz et al. | Causes of gynaecomastia in young adult males and factors associated with idiopathic gynaecomastia | |
| Aranda et al. | Effects of sex steroids on cardiovascular risk profile in transgender men under gender affirming hormone therapy | |
| Salminen et al. | Estradiol and cognition during androgen deprivation in men with prostate carcinoma | |
| JP2009525478A5 (enExample) | ||
| Yang et al. | NU7441 enhances the radiosensitivity of liver cancer cells | |
| Zahran et al. | Increased frequency and FOXP3 expression of human CD8+ CD25High+ T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma | |
| Treska et al. | Hepatic epithelioid hemangioendothelioma–a rare tumor and diagnostic dilemma | |
| Counts et al. | The effect of estradiol administration on muscle mass loss and cachexia progression in female Apc Min/+ mice | |
| ATE497165T1 (de) | Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung | |
| de la Torre et al. | A phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect | |
| RU2012148816A (ru) | Метод диагностики для определения клеток ex vivo | |
| Sakata et al. | Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function | |
| Saifi et al. | Comparable efficacy of reduced dose radiation therapy for the treatment of early stage gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue | |
| Hsu et al. | Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels | |
| Überall et al. | Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer | |
| Kim et al. | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | |
| Zhao et al. | Positivity of both plasma Epstein–Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma | |
| Kobayashi et al. | Subtype prediction in primary aldosteronism: measurement of circadian variation of adrenocortical hormones and 24‐h urinary aldosterone | |
| Wu et al. | Ferroptosis involves in Schwann cell death in diabetic peripheral neuropathy | |
| Lan et al. | Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer | |
| Khan et al. | Depression enhanced the production of autoantibodies against 16α‑hydroxyestrone-estrogen receptor adduct in breast cancer | |
| Gritzapis et al. | Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assay | |
| Mehrabian et al. | Can sex-hormone binding globulin considered as a predictor of response to pharmacological treatment in women with polycystic ovary syndrome? |